SCHEMBL2400129

SCHEMBL2400129

CCCOCCOCC[O]

nearest known ligand 0.37

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.37
CYP3A4 P08684 1/20 0.37
HSD17B10 Q99714 1/20 0.36
MEN1 O00255 1/20 0.33
THRB P10828 1/20 0.33
HTT P42858 1/20 0.33
KMT2A Q03164 1/20 0.33
MAPT P10636 1/20 0.33
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4272396 1.00 TSHR (0.37) TSHRCYP3A4HSD17B10MEN1THRB
SCHEMBL28639640 1.00 TSHR (0.37) TSHRCYP3A4HSD17B10MEN1THRB
SCHEMBL431426 0.97
SCHEMBL4397632 0.88 HTT (0.41) TSHRCYP3A4HSD17B10MEN1THRB
SCHEMBL4398847 0.88 TSHR (0.40) TSHRCYP3A4HSD17B10MEN1THRB
SCHEMBL4393750 0.85
SCHEMBL17586846 0.83 HSD17B10 (0.45) TSHRCYP3A4HSD17B10MEN1THRB
SCHEMBL272664 0.83 HSD17B10 (0.45) TSHRCYP3A4HSD17B10MEN1THRB
SCHEMBL7799602 0.83 HSD17B10 (0.45) TSHRCYP3A4HSD17B10MEN1THRB
SCHEMBL116376 0.83 HSD17B10 (0.45) TSHRCYP3A4HSD17B10MEN1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239922-A1 PHOTOCURABLE COMPOSITION TOKYO OHKA KOGYO CO., LTD. (JP) 2024-07-18 US disclosed
US-20240192593-A1 PHOTOSENSITIVE COMPOSITION TOKYO OHKA KOGYO CO., LTD. (JP) 2024-06-13 US disclosed
US-20240191003-A1 COMPOSITION AND PHOTOSENSITIVE COMPOSITION TOKYO OHKA KOGYO CO., LTD. (JP) 2024-06-13 US disclosed
CN-114423742-B Benzotriazole-based compound, light absorber and resin composition 三井化学株式会社 2024-05-28 CN disclosed
US-11981794-B2 Curable composition, cured product, and compound TOKYO OHKA KOGYO CO., LTD. (JP) 2024-05-14 US disclosed
CN-117999296-A Composition and photosensitive composition 东京应化工业株式会社 2024-05-07 CN disclosed
CN-117980347-A Photosensitive composition 东京应化工业株式会社 2024-05-03 CN disclosed
CN-117980346-A Composition and photosensitive composition 东京应化工业株式会社 2024-05-03 CN disclosed
US-20240141085-A1 PHOTOCURABLE LIQUID COMPOSITION, CURED PRODUCT, AND METHOD FOR PRODUCING CURED PRODUCT TOKYO OHKA KOGYO CO., LTD. (JP) 2024-05-02 US disclosed
US-20240132675-A1 POLYMER HAVING METAL-OXYGEN-METAL BOND AS PRIMARY CHAIN, COMPOSITION THEREOF, SOLID MATERIAL AND PRODUCTION METHOD THEREOF, AND ELECTRONIC COMPONENT AND FIBER TORAY INDUSTRIES, INC. (JP) 2024-04-25 US disclosed
EP-0536936-A1 Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use Sankyo Company Limited (JP) 1993-04-14 EP disclosed
EP-0149760-B1 SUBSTITUTED O-ACYL GLYCOSYLAMIDES, METHODS FOR THEIR PREPARATION AND THEIR USE BAYER AG (DE) 1989-08-23 EP disclosed
EP-0193887-B1 SUBSTITUTED O-SULFONYL-GLYCOSYL AMIDES, METHOD FOR THEIR PREPARATION AND THEIR USE AS MEDIACMENTS BAYER AG (DE) 1989-07-26 EP disclosed
US-4716152-A IMMUNOSTIMULANTS BAYER AKTIENGESELLSCHAFT (DE) 1987-12-29 US disclosed
US-4699899-A IMMUNE STIMULANTS BAYER AKTIENGESELLSCHAFT (DE) 1987-10-13 US disclosed
EP-0193887-A2 Substituted O-sulfonyl-glycosyl amides, method for their preparation and their use as mediacments BAYER AG (DE) 1986-09-10 EP disclosed
US-4574122-A ANTIBODIES, IMMUNOLOGY BAYER AKTIENGESELLSCHAFT (DE) 1986-03-04 US disclosed
EP-0149760-A2 Substituted O-acyl glycosylamides, methods for their preparation and their use BAYER AG (DE) 1985-07-31 EP disclosed
EP-0144894-A2 Therapeutic application of substituted O-acyl-glycosides BAYER AG (DE) 1985-06-19 EP disclosed
US-3941804-A 1-Heteroarylsulphonyl-2-imino-imidazolidines CIBA-GEIGY CORPORATION (US) 1976-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240192593-A1 PHOTOSENSITIVE COMPOSITION PPOX, ERCC1, ERCC5 TSHR 4858/4885CYP3A4 3674/4885HSD17B10 3320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.